sisunatovir + midazolam (Pfizer)

**sisunatovir + midazolam** is a combination used in clinical research to assess the potential pharmacokinetic drug-drug interactions between **sisunatovir** and **midazolam**. Sisunatovir is an orally administered small molecule inhibitor of the Respiratory Syncytial Virus (RSV) fusion (F) protein, developed to block viral entry and cell-to-cell fusion, thereby limiting RSV infection. Midazolam is commonly used as a sensitive probe substrate for the cytochrome P450 3A4 (CYP3A4) enzyme to assess the potential for drug interactions because its metabolism is highly dependent on CYP3A4 activity. In studies, midazolam is given together with sisunatovir to evaluate whether sisunatovir affects CYP3A4-mediated metabolism, which is relevant for predicting drug-drug interactions[1][3].